Repligen (NASDAQ:RGEN – Get Free Report) posted its quarterly earnings results on Tuesday. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33, Briefing.com reports. Repligen had a return on equity of 3.95% and a net margin of 2.44%. The firm had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. During the same quarter in the prior year, the firm posted $0.53 EPS. The company’s revenue for the quarter was down 3.2% on a year-over-year basis. Repligen updated its FY24 guidance to $1.42-1.49 EPS and its FY 2024 guidance to 1.420-1.490 EPS.
Repligen Stock Up 1.3 %
RGEN traded up $2.01 during trading on Wednesday, reaching $162.60. 38,544 shares of the stock were exchanged, compared to its average volume of 624,833. Repligen has a twelve month low of $110.45 and a twelve month high of $211.13. The stock has a market cap of $9.09 billion, a P/E ratio of 642.39, a price-to-earnings-growth ratio of 4.62 and a beta of 0.95. The stock’s 50 day moving average price is $134.67 and its two-hundred day moving average price is $166.12. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.35.
Insider Buying and Selling at Repligen
In other Repligen news, Director Martin D. Madaus purchased 1,615 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were acquired at an average cost of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the purchase, the director now owns 4,613 shares of the company’s stock, valued at approximately $576,348.22. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Martin D. Madaus acquired 1,615 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The stock was acquired at an average price of $124.94 per share, with a total value of $201,778.10. Following the completion of the transaction, the director now directly owns 4,613 shares of the company’s stock, valued at approximately $576,348.22. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Anthony Hunt sold 20,072 shares of the company’s stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the sale, the chief executive officer now directly owns 163,177 shares of the company’s stock, valued at approximately $27,456,162.02. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company’s stock.
Wall Street Analyst Weigh In
Read Our Latest Stock Report on RGEN
About Repligen
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Recommended Stories
- Five stocks we like better than Repligen
- Find and Profitably Trade Stocks at 52-Week Lows
- Conviction Firms for Microsoft’s Double-Digit Stock Upside
- About the Markup Calculator
- 5 Aggressive Growth Stocks for Long-Term Investors
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Invest Like Congress: 2 ETFs to Add to Your Watchlist
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.